Adaptive Biotechnologies Corp 8-K

What Happened Adaptive Biotechnologies Corporation (ADPT) filed an 8-K on June 9, 2026 reporting the results of its annual meeting held June 5, 2026. Shareholders elected two Class I directors — Robert Hershberg, PhD, MD, and Katey Owen, PhD — approved an advisory vote on 2025 executive compensation (say‑on‑pay), and ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending December 31, 2026. The proposals were described in the company’s definitive proxy statement filed April 24, 2026.

Key Details

• Robert Hershberg: 93,188,652 votes FOR (71.81%); 36,573,708 WITHHOLD/ABSTAIN (28.19%); broker non‑votes: 13,570,859.
• Katey Owen: 126,803,695 votes FOR (97.72%); 2,958,666 WITHHOLD/ABSTAIN (2.28%); broker non‑votes: 13,570,859.
• Advisory vote on 2025 named executive officer compensation: 125,287,618 FOR (96.55%); 4,316,144 AGAINST (3.33%); 158,599 WITHHOLD/ABSTAIN (0.12%); broker non‑votes: 13,570,859.
• Ratification of Ernst & Young LLP as auditor: 142,609,643 FOR (99.50%); 484,798 AGAINST (0.34%); 238,779 WITHHOLD/ABSTAIN (0.17%); broker non‑votes: 0.

Why It Matters

• Board and governance: The election results confirm the board’s Class I directors and reflect differing levels of shareholder support for the two nominees (notably higher withhold for Dr. Hershberg).
• Executive pay oversight: The strong advisory support for 2025 executive compensation (96.55% FOR among votes cast) gives the board a clear, non‑binding endorsement from shareholders.
• Audit continuity: Ratification of Ernst & Young preserves auditor continuity for 2026, which is material for financial reporting and investor assurance.

This 8-K is a factual report of shareholder voting outcomes; it does not announce operational or financial changes.